JP2011524741A5 - - Google Patents

Download PDF

Info

Publication number
JP2011524741A5
JP2011524741A5 JP2011511785A JP2011511785A JP2011524741A5 JP 2011524741 A5 JP2011524741 A5 JP 2011524741A5 JP 2011511785 A JP2011511785 A JP 2011511785A JP 2011511785 A JP2011511785 A JP 2011511785A JP 2011524741 A5 JP2011524741 A5 JP 2011524741A5
Authority
JP
Japan
Prior art keywords
antibody
partial sequence
subsequence
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011511785A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011524741A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/045322 external-priority patent/WO2009154995A2/en
Publication of JP2011524741A publication Critical patent/JP2011524741A/ja
Publication of JP2011524741A5 publication Critical patent/JP2011524741A5/ja
Withdrawn legal-status Critical Current

Links

JP2011511785A 2008-05-27 2009-05-27 インターロイキン１０受容体（ｉｌ−１０ｒ）抗体及び使用方法 Withdrawn JP2011524741A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5629908P 2008-05-27 2008-05-27
US61/056,299 2008-05-27
PCT/US2009/045322 WO2009154995A2 (en) 2008-05-27 2009-05-27 Interleukin 10 receptor (il-10r) antibodies and methods of use

Publications (2)

Publication Number Publication Date
JP2011524741A JP2011524741A (ja) 2011-09-08
JP2011524741A5 true JP2011524741A5 (enExample) 2012-06-28

Family

ID=41434638

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011511785A Withdrawn JP2011524741A (ja) 2008-05-27 2009-05-27 インターロイキン１０受容体（ｉｌ−１０ｒ）抗体及び使用方法

Country Status (4)

Country Link
US (1) US8420784B2 (enExample)
EP (1) EP2293667A4 (enExample)
JP (1) JP2011524741A (enExample)
WO (1) WO2009154995A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2543727B1 (en) 2010-03-02 2016-08-31 Kyowa Hakko Kirin Co., Ltd. Modified antibody composition
WO2013086019A1 (en) * 2011-12-06 2013-06-13 Massachusetts Institute Of Technology Use of humanized mice to determine toxicity
JP2016507555A (ja) * 2013-02-06 2016-03-10 インヒブルクス エルピー 血小板非減少性かつ赤血球非減少性ｃｄ４７抗体及びその使用方法
WO2016027697A1 (ja) * 2014-08-22 2016-02-25 日東紡績株式会社 ＴＲＡＣＰ－５ｂ（酒石酸抵抗性酸性フォスファターゼ５ｂ）に特異的なタンパク定量法
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
WO2018045273A2 (en) * 2016-09-02 2018-03-08 The Brigham And Women's Hospital, Inc. Compositions and methods for treating neoplasias
AU2017336546C1 (en) 2016-09-27 2025-05-29 Epicentrx, Inc. Immunomodulatory fusion proteins
ES2952744T3 (es) 2016-12-15 2023-11-03 Nestle Sa Composiciones y procedimientos que modulan los glóbulos blancos o los neutrófilos en un animal de compañía
US10894833B2 (en) * 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
KR102757384B1 (ko) * 2017-09-27 2025-01-20 에피센트알엑스, 인코포레이티드 면역조절 융합 단백질
EP3836955A4 (en) * 2018-08-15 2022-05-18 The Regents of the University of California IL-10 INHIBITION FOR VACCINES AND IMMUNOTHERAPY
US20220144911A1 (en) * 2019-02-01 2022-05-12 Uab Research Foundation Methods and compositions for il10 signaling antagonism
KR102517872B1 (ko) * 2019-06-12 2023-04-05 (주)아큐레시스바이오 암의 예방 또는 치료용 조성물
WO2022031885A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il10ra binding molecules and methods of use
JP7819178B2 (ja) * 2020-08-05 2026-02-24 シンセカイン インコーポレイテッド ＩＬ１０Ｒｂ結合分子および使用方法
US12540188B2 (en) 2020-08-05 2026-02-03 Synthekine, Inc. IL10Rα/IL2Rγ synthetic cytokines
KR20240114801A (ko) * 2023-01-17 2024-07-25 한양대학교 산학협력단 Il-10 수용체에 특이적으로 결합하는 항체 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884413B1 (en) * 1999-03-24 2005-04-26 The United States Of America As Represented By The Department Of Health And Human Services Induction of antigen-specific unresponsiveness by glioblastoma culture supernatants (GCS)
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
EP1439223A1 (en) * 2001-10-02 2004-07-21 Mochida Pharmaceutical Co., Ltd. Novel class ii cytokine receptor
GB0302167D0 (en) * 2003-01-30 2003-03-05 Leuven K U Res & Dev T cell phenotype
US7651855B2 (en) 2003-04-17 2010-01-26 The Trustees Of The University Of Pennsylvania Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
EP2857418B1 (en) 2004-02-06 2017-07-26 University of Massachusetts Antibodies against Clostridium difficile toxins and uses thereof

Similar Documents

Publication Publication Date Title
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
RU2011129204A (ru) Антитела против ангиопоэтина-2 человека
MX2011008843A (es) Anticuerpos humanizados que se unen a cd19 y sus usos.
JP2015522252A5 (enExample)
EA201370105A1 (ru) Человеческие антитела против человеческого tnf-подобного лиганда-1а (tl1a)
PE20120211A1 (es) Anticuerpos que tienen especificidad por ox40 humana
JP2011515073A5 (enExample)
GEP20115324B (en) Tweak binding antibodies
JP2011501945A5 (enExample)
PE20120343A1 (es) Anticuerpo anti-cmet que comprende una region bisagra
EA201290173A1 (ru) Антитела против эндоглина
JP2012502649A5 (enExample)
PE20131465A1 (es) Moleculas de union a 4-1 bb
MX355181B (es) Anticuerpos humanos contra el factor tisular.
CO6231009A2 (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
JP2017522903A5 (enExample)
JP2012511913A5 (enExample)
RU2012129735A (ru) Антитела к her3 и их применения
CO6331370A2 (es) Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos
JP2016515524A5 (enExample)
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NO20083793L (no) Antistoffer mot amyloid-beta peptid
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
JP2011157378A5 (enExample)
JP2012070740A5 (enExample)